找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Management of Pancreatic Cancer and Cholangiocarcinoma; Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki Book 2021 The Editor(s) (if applicab

[復(fù)制鏈接]
查看: 19706|回復(fù): 53
樓主
發(fā)表于 2025-3-21 19:42:08 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma
編輯Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki
視頻videohttp://file.papertrans.cn/623/622569/622569.mp4
概述Covers recent topics in epidemiology, examination, treatment and endoscopic management of pancreatobiliary malignancies.Will appeal to surgeons, endoscopists and oncologists.Explores risk factors and
圖書封面Titlebook: Management of Pancreatic Cancer and Cholangiocarcinoma;  Hiroyuki Isayama,Yousuke Nakai,Takashi Sasaki Book 2021 The Editor(s) (if applicab
描述.This comprehensive book presents the latest evidence-based data on pancreatobiliary malignancies, including the epidemiology, examination, treatment and endoscopic management. It explores a range of topics, such as risk factors, detection strategies, and novel treatment approaches like precision medicine and immunotherapy..Although there have been rapid improvements in the management of these diseases, the survival period has not yet reached a satisfactory level. This book will help those doctors needing to share the latest information with the patients and their families. It provides a wealth of practical information to help surgeons, endoscopists and oncologists as well as physicians, basic researchers and professionals at medical device and pharmaceutical companies broaden their understanding of the current treatment and management strategies for pancreatobiliary malignancies..
出版日期Book 2021
關(guān)鍵詞Pancreas Cancer; Bile Duct Cancer; Cholangiocarcinoma; Surgery; Endoscopic Treatment; Interventional EUS;
版次1
doihttps://doi.org/10.1007/978-981-16-2870-2
isbn_softcover978-981-16-2872-6
isbn_ebook978-981-16-2870-2
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor
The information of publication is updating

書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma影響因子(影響力)




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma影響因子(影響力)學(xué)科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma網(wǎng)絡(luò)公開度




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma被引頻次




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma被引頻次學(xué)科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma年度引用




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma年度引用學(xué)科排名




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma讀者反饋




書目名稱Management of Pancreatic Cancer and Cholangiocarcinoma讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 22:45:44 | 只看該作者
Book 2021and endoscopic management. It explores a range of topics, such as risk factors, detection strategies, and novel treatment approaches like precision medicine and immunotherapy..Although there have been rapid improvements in the management of these diseases, the survival period has not yet reached a s
板凳
發(fā)表于 2025-3-22 03:44:42 | 只看該作者
地板
發(fā)表于 2025-3-22 05:53:47 | 只看該作者
5#
發(fā)表于 2025-3-22 10:40:35 | 只看該作者
6#
發(fā)表于 2025-3-22 13:08:02 | 只看該作者
7#
發(fā)表于 2025-3-22 18:51:00 | 只看該作者
8#
發(fā)表于 2025-3-22 22:11:03 | 只看該作者
Radiotherapy for Pancreatic Cancern. The life-prolonging effect of radiotherapy has not yet been clearly demonstrated, but it has been shown to lead to improved local control. In this chapter, we will introduce radiotherapy for pancreatic cancer, focusing on the heavy-ion radiotherapy that we are performing.
9#
發(fā)表于 2025-3-23 05:19:42 | 只看該作者
Conversion Surgery in Pancreatic Cancerthere are no robust data which indicate the clear benefit of CS and no consensus of the indication and optimal timing of CS for initially unresectable pancreatic cancer. Several prospective clinical trials are ongoing to clarify the benefit of CS for UR-PDAC.
10#
發(fā)表于 2025-3-23 09:11:43 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-30 07:31
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
湖北省| 洱源县| 桐庐县| 房产| 富平县| 建阳市| 绥棱县| 苏州市| 富蕴县| 弋阳县| 乳源| 鹰潭市| 理塘县| 原平市| 东乡县| 仲巴县| 兰坪| 台中县| 海晏县| 察哈| 日土县| 卢氏县| 宿迁市| 邳州市| 西乌珠穆沁旗| 大名县| 宁蒗| 中超| 大竹县| 邵阳市| 无锡市| 巴南区| 泰宁县| 屯门区| 庆云县| 隆林| 孟连| 乌苏市| 高雄市| 宿迁市| 南昌县|